Tech Center 1600 • Art Units: 1600 1622 1625 1654
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | Non-Final OA | Genzyme Corporation |
| 17602103 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Non-Final OA | JAPAN TOBACCO INC. |
| 18564839 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN NEURODEGENERATIVE DISORDERS | Non-Final OA | Universiteit Hasselt |
| 18558113 | HYDROXYBISPHOSPHONIC DERIVATIVES OF MELOXICAM FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES | Non-Final OA | Atlanthéra |
| 18547252 | TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS | Non-Final OA | SYNAPTOGENIX, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy